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Steady Improvement in renal allograft survival among North American
children. From 1987 through 1994, the North American Pediatric Renal
Transplant Cooperative Study (NAPRTCS) has enrolled 1641 cadaver
donor transplants. For this study, we have analyzed one and two year graft
survival by annual cohorts for the years 1987 through 1991. For the 1987
cohort one and two year graft survival was 72% and 65%, respectively, and
for the 1991 cohort it was 83% and 78%, respectively. Using a propor-
tional hazards model, and comparing the 1987 cohort to the 1991 cohort,
the relative risk for graft failure was 1.40 (P = 0.02). Analysis of practice
patterns revealed the following changes which may have been associated
with this improved graft survival: (1) use of T cell induction antibody, 38%
in 1987 and 67% in 1991 (P  0.001); (2) the increased use of cyclosporine(CsA) post-transplant: in 1987, 87% were maintained on CsA at day 30
compared to 97% in 1991 (P < 0.001); (3) the mean higher daily
maintenance CsA dose at 12 months post-transplant which in 1987 was 6.5
mg/kg compared to 7,5 mg/kg in 1991 (P = 0.03); (4) the decreased use of
random transfusions, 54% receiving >5 transfusions in 1987 compared to
37% in 1991 (P < 0.001);and (5) decreased use of younger cadaver donors
between 1987 and 1991 (P < 0.001).
Renal transplantation is considered the optimal replacement
therapy for children with end-stage renal disease (ESRD). More
than 25% of the pediatric ESRD population in the United States
and Canada never undergoes dialysis but receives a renal trans-
plant preemptively [1]. Unfortunately, the outcome of renal
transplantation in children has been inferior to the results ob-
served in adults. The North American Pediatric Renal Transplant
Cooperative Study (NAPRTCS) was organized in 1987 to register
and follow children up to 17 years of age who receive renal
allografts in the United States and Canada. Since its inception, the
83 participating Centers have registered 3438 transplants. This
report analyzes data from the first five years of the registry
(1987-1991) to define trends in cadaver graft outcome and identify
the practice patterns which may have been contributory to
changes in that outcome. There has been a secular trend to steady
improvement in transplant outcome in children in the study group
felt to be a consequence of alterations in clinical practice identi-
fied by the North American Pediatric Renal Transplant Cooper-
ative Study.
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Methods
The NAPRTCS is made up of a Clinical Coordinating Center,
a Data Coordinating Center and 83 participating centers treating
children with renal disease in the United States and Canada.
Methods of data collection have been reported previously [2].
Briefly these methods consist of collecting information at 30 days
following a transplant, then additional status information at each
six month interval post-transplantation. The data collected in-
clude information regarding immunosuppression therapy, epi-
sodes of graft rejection and patient morbidity as determined by
hospitalization post-transplantation. Separate data are also col-
lected for each graft failure and for patient death.
Statistical analysis
Standard univariate and multivariate statistical methods, in-
cluding product-limit estimates of survival distributions, were
used to analyze the data. Proportional-hazards survival models
were constructed that equated an individual patient's hazard to an
underlying hazard multiplied by an estimated exponentiated
linear combination of risk factors. Multivariate models were
scaled so that risk increased with larger values of the covariates;
the relative risk for a single dichotomous risk factor is the
exponentiated parameter.
Results
From January 1987 through December 1991, 1410 cadaver
donor transplants were performed, of which 1258 were index
transplants. (An index transplant is the first transplant reported to
the NAPRTCS for a patient since the study began in January
1987.) Plots of graft survival distributions of index transplants, by
annual cohort, are shown in Figure 1. The one year graft survival
percentages for the annual cohorts are 72% (N = 202) for 1987,
70% (N = 190) for 1988, 77% (N = 169) for 1989, 80% (N = 200)
for 1990, and 83% (N = 157) for 1991. Two year graft survival
percentages are 65% (N = 175), 62% (N = 160), 73% (N = 148),
76% (N = 172), and 78% (N = 86), respectively, for 1987 through
1991.
Since there are multiple variables that influence cadaver graft
survival, proportional hazards regression models were used to
determine if transplant year was a significant concomitant risk
factor. The risk factors of graft failure are shown in Table 1, with
the relative risk increases and P values. In order to remove any
bias associated with technical graft losses, Table 1 also presents
551
552 Tejani et a!: Improved survival in pediatric transplantation
CD transplants
All CD lasting
transplants  30 days
RR P value RR P value
Recipient age (<2) 2.35 <0.001 1.89 0.012
Donor age (<6) 1.48 <0.001 1.35 0.020
Prior transplant 1.44 0.001 1.28 0.075
ATG/ALG/OKT3 early 1.42 <0.001 1.28 0.030
administration (none)
>5 Lifetime transfusions 1.30 0.006 1.42 0.002
Annual cohort (1987 vs. 1991) 1.40 0.023 1.50 0.037
Recipient race (black) 1.27 0.034 1.26 0.091
No DR matches 1.25 0.015 1.31 0.014
estimates of relative risk for these variables conditional on the
graft having survived for at least 30 days.
In addition, we reviewed changes in clinical practice patterns
over the five year period, especially changes in the use of
immunosuppressive therapy, both at the time of grafting and
during the maintenance phase that may account for the improve-
ment in graft outcome. We observed that in 1987 only 38% of
cadaver donor transplant recipients received anti-T cell induction
therapy in the form of either ATG, ALG, or OKT3, whereas in
1991 67% of all cadaver donor transplant recipients were treated
with anti-T cell induction therapy (P < 0.001).
Analysis of cyclosporine dosing showed that in 1987 87% of all
cadaver donor transplant recipients were being maintained on cyclo-
sporine at day 30 post-transplantation, compared to 97% of all
cadaver donor transplant recipients in 1991 (P < 0.001). We also
noted that the mean daily maintenance dose of cyclosporine at 12
months post-transplantation in 1991 was higher at 7.5 mg/kg (SD =
4.6) compared to 65 mg/kg (SD = 4.2) in 1987 (P = 0.033). To
determine the relationship of cyclosporine dose to changes in graft
survival, the conditional analysis of graft survival was repeated in a
model that included a time dependent term for cyclosporine dose
(Table 2). Introduction of the cyclosporine dose into the hazard
model diminished the significance of the year of transplant, suggest-
ing a correlation between higher cyclosporine doses and improved
graft survival. An analysis that included only cyclosporine dose (RR
= 0.95,P < 0.001) and year of transplants (1987 vs. 1991, RR = 1.76,P = 0.002) indicates that cyclosporine dose alone does not remove
the significance of transplant year.
Changes in clinical practice patterns were also examined re-
Relative
risk increase P value
Recipient age (<2) 2.02 0.006
Donor age (<6) 1.37 0.014
Prior transplant 1.28 0.068
ATG/ALG/OKT3 early administration (none) 1.26 0.039
>5 Lifetime transfusions 1.44 0.004
Annual cohort (1987 vs 1991) 1.41 0.075
Recipient race (black) 1.31 0.045
No DR matches 1.34 0.008
Cyclosporine dose mg/kr 0.95 <0.001
a At day 30, 6 months, and every 6 months thereafter
garding transfusion therapy and the use of young cadaver donors.
Whereas 54% of all cadaver donor recipients in 1987 received >5
random transfusions, only 37% of cadaver donor recipients in
1991 received >5 random transfusions (P < 0.001).
There were also significant changes in the distribution of
cadaver donor ages between 1987 and 1991 (P < 0.001). In 1987
4% (12 of 299) of cadaver donors were less than two years of age
and 18% (53 of 299) were between the ages of 2 and 5.
Comparatively, there were no cadaver donors less than two years
of age and only 11% (28 of 248) were between the ages of 2 and
5 in 1991. While 58% of cadaver donors in 1987 were older than
12 years, 75% in 1991 were of similar age.
Discussion
The NAPRTCS is a research effort organized in 1987 with a
specific aim of capturing information about current practices and
trends in immunosuppression therapy with an ultimate goal of
improving care of pediatric renal allograft recipients in North
America. The initial analysis of 390 children receiving a renal
allograft was presented in 1988 [3]. Since then, factors which
impact on graft survival have been regularly evaluated [2, 4, 5].
Under the aegis of NAPRTCS, changes in practice have steadily
improved outcome in children from those described by the
registry and from the first cohort of the group.
Antibody induction introduced in the study group may have
contributed to the improvement in graft outcome in children.
Antibody based induction protocols have been utilized for more
than two decades, but the results of their use have been contro-
versial. Sequential therapy using Minnesota Antilymphoblast
Globulin (MALG) was first described in 1985 [6]. Since then it has
been extensively used in adults with improved graft survival rates
[7]. In a single center randomized study, Goldman et al [8] noted
an improved early graft survival rate in OKT3 treated patients
compared to those with conventional therapy. In a multicenter
trial of adult CD transplant recipients, induction with OKT3 lead
to a 8 to 9% increase in graft survival rate; however, the
improvement was not statistically significant [9]. Available data on
the use of sequential therapy with either MALG, ATG or OKT3
in pediatric allograft recipients are limited. The beneficial effect of
anti-T cell induction in pediatric CD recipients with the use of
antibody preparations was initially described in the NAPRTCS
1990 report [10] and the beneficial effect persists [2]. The most
recent analysis [1] noted that the CD graft survival rate in 944
children not receiving anti-T cell induction was 60% compared to
70% in 698 children who received induction therapy. Additionally,
NAPRTCS data indicated that the use of anti-T cell induction
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Fig. 1. Two yeaia graft survival distribution for years 1987 through 1991.
Table 1. Risk of graft failure based on a proportional hazards model
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therapy can obviate any adverse impact of poor HLA matching.
No differences have been seen in the one and two years graft
survival rate of poorly HLA matched, anti-T cell induced recipi-
ents, whereas HLA matching has been important in graft outcome
in the non-anti-T cell induced recipient group (P < 0.04) [11}.
A second factor in the improvement in graft outcome in
children may be reduction in the use of transfusions. Data from
the UCLA Transplant registry reveal that the proportion of
transfused to nontransfused patients has decreased from a ratio of
10:1 in 1981 to 1:1 in 1990 [12]. Furthermore, the beneficial effect
of transfusions first noted in 1981 has disappeared [13, 14].
Previously, we have not been able to document that >5 transfu-
sions is detrimental to CD graft survival rates, but with a larger
population and longer follow-up our data confirm the observation
seen in adult recipients. Therefore, the decreasing frequency of
37% in 1991 compared to 54% in 1987 is a reflection of improved
clinical practice and of the increasing use of erythropoietin, which
was released for use in dialysis patients in 1990.
The dosing of cyclosporine A which takes into account the
peculiar metabolism and immune systems of children culminating
in the use of higher doses may also have contributed to the
improved graft survival that we are exhibiting in this study.
Previous data from NAPRTCS demonstrated that lower mainte-
nance doses of CsA are associated with a higher frequency of
rejection and graft failure [15]. This finding has been observed by
Solomon [16] in adult recipients. More pertinent was the obser-
vation that the 1991 cohort is being maintained on a higher dose
(7.5 mg/kg/day) compared to the 1987 cohort (6.5 mg/kg/day).
When the cyclosporine dose is entered into the proportional
hazards model as a time dependent variable as shown in Table 2
the annual cohort effect ceases to be significant. This finding
points strongly to an important influence of cyclosporine dose in
improving graft survival in 1991.
Lastly, the avoidance in later cohorts of transplantation be-
tween the youngest donor and youngest recipient may also be a
contributing factor in the observed improved graft survival. We
have previously noted that when there is a concordance between
young recipient age and young cadaver donor age, graft survival is
markedly inferior [17]. In a special analysis of cadaver donor
transplants done from 1987 through 1990 [18], we noted that the
risk of graft loss from a neonatal donor was 2.7-fold that of the
ideal donor. We also noted that 10% of grafts from cadaver
donors <5 years of age are lost due to vascular thrombosis,
primary non-function and other technical causes. Obviously, the
greater use of older cadaver donors, which reached 75% in 1991,
has had a beneficial impact on graft survival.
Some factors that increase the relative risk of cadaver graft
failure in children such as recipient age are integral to pediatrics,
others such as recipient race, the degree of HLA matching, and
prior transplantation are factors that cannot be easily manipu-
lated. Improvement in cadaver allograft survival rates, however,
can be achieved by judicious choice of donors, pretranspiant
management, manipulation of induction therapy, and by optimal
maintenance immunosuppressive therapy. The observation that
improvement in cadaver graft survival rates is correlated with
changing practice patterns confirms the original intent of
NAPRTCS. As our data base grows, it is anticipated that identi-
fication of various factors which impact on graft survival will lead
to improved graft survival rates, thereby improving the quality of
life in children following renal transplantation.
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